Background: Endocrine influences on the human voice remain insufficiently characterized compared with biomechanical and acoustic domains. Across the lifespan, hormonal transitions—including puberty, menstrual cycling, pregnancy, postpartum recovery, perimenopause, and menopause—alter vocal fold tissue composition, vibratory behavior, and respiratory-phonatory coordination. Peer-reviewed evidence indicates that hormone replacement therapy (HRT) can mitigate postmenopausal lowering of fundamental frequency, while androgen exposure in cisgender women may cause irreversible pitch lowering and roughness (Lin et al., 2020; D’haeseleer et al., 2012; Chadwick et al., 2021; Majeethia et al., 2025). Cyclical and gestational hormonal changes are linked to transient dysphonia, edema, and reduced maximum phonation time, with postpartum pitch lowering observed (Gunjawate et al., 2017; Hamdan et al., 2009; Saltürk et al., 2016; Pisanski et al., 2018). Beyond sex steroids, emerging reports suggest that GLP-1 receptor agonists, increasingly prescribed for metabolic regulation, may influence hydration, muscle tone, and respiratory support, warranting investigation into potential vocal sequelae. Yet most voice research lacks hormonal assays, endocrine controls, or longitudinal design, underscoring the need for integrative, evidence-based frameworks.

Objective: This multidisciplinary panel session unites current research and clinical perspectives on endocrine and psychogenic influences on voice. Presenters from otolaryngology, speech-language pathology, and voice pedagogy will synthesize findings on:
(1) HRT and menopausal voice;
(2) androgen supplementation and cisgender female outcomes;
(3) menstrual-cycle-related acoustic and perceptual changes;
(4) pregnancy and postpartum effects;
(5) psychogenic–endocrine interactions; and
(6) potential voice implications of GLP-1 medications.
The goal is to translate recent data into practical diagnostic and management strategies for ENTs, SLPs, and singing-voice teachers.

Methods: Multi-disciplinary voice practitioner panelists review peer-reviewed data and present new observations from each of their areas of expertise and recent research, including laboratory, clinical, and pedagogical contexts. Shared variables include hormonal status (natural or medically modulated), acoustic and aerodynamic metrics, stroboscopic findings, and patient-reported outcomes. Comparative analyses across reproductive phases and medication states highlight methodological constraints, including lack of endocrine biomarkers, small sample sizes, and inconsistent timing of measurement relative to hormonal cycles.

Results/Conclusions: Endocrine milieu and pharmacologic modulation substantially influence vocal function. Incorporating hormonal and metabolic literacy—including awareness of GLP-1 therapies—into voice care enhances differential diagnosis and personalized intervention. This panel underscores the need for longitudinal, biomarker-informed research and cross-disciplinary collaboration among ENTs, SLPs, endocrinologists, and voice educators to optimize vocal health across life stages and treatment contexts.